GleamWall
中文EN

NPHC NUTRA PHARMA CORP

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1119643 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-49.0%
TTM net income YoY-255.0%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—

Margins

Gross margin64.8%
Operating margin-1,017.8%
Net margin-3,370.6%
FCF margin—
EBITDA margin-1,011.4%

Returns

ROE—
ROA-731.5%
ROIC (approx.)—
Asset turnover0.22x

Leverage & solvency

Liabilities / assets3,505.0%
Debt / equity—
Current ratio0.02x
Interest coverage-68.24x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-589.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$34,463$27,246$28,864$70,242$84,532$73,974$81,873$74,994
Cost of revenue$25,297$29,239$65,973$34,128$58,715$46,263$175,672$23,777
Gross profit$32,625$18,975-$11,907$64,576$63,428$59,131$86,588$70,693
SG&A expense———$420,652$366,157$418,150$265,455$255,445
Operating income-$435,464-$379,249-$465,914-$356,076-$290,529-$349,819-$178,867-$184,752
Interest expense$6,248$6,002$5,955$5,780$5,550$5,585$5,577$5,413
Pretax income-$3.95M-$459,675-$488,526-$523,520$369,577-$1.40M-$230,907-$260,683
Net income-$3.95M-$459,675-$488,526-$523,520$369,577-$1.40M-$230,907-$260,683
EBITDA-$433,106-$376,748-$463,342-$353,307-$287,366-$347,674-$177,007-$182,892
EPS (basic)0.000.00—0.000.000.00—0.00
EPS (diluted)0.000.00—0.000.000.00—0.00
Weighted avg. shares (diluted)8.07B8.01B—7.82B37.73B7.68B—7.66B
Balance sheet
Cash & equivalents—$21,844$12,181$3,603$79,069$13,843$36,447$0
Short-term investments$17,600$17,600$17,600$17,600$17,600$17,600$17,600$17,600
Receivables———————$23,149
Inventory$23,509$23,506$19,535$17,518$15,658$17,571$17,696$17,073
Current assets$463,119$499,424$459,583$545,106$665,128$552,117$374,837$310,755
PP&E, net$20,946$23,304$25,805$28,377$31,146$34,309$10,402$12,262
Total assets$622,863$616,518$622,601$709,853$859,068$775,179$599,495$558,838
Current liabilities$21.70M$17.74M$17.31M$16.92M$16.55M$16.85M$15.27M$15.21M
Short-term debt$12.44M$9.87M$9.62M$9.54M$9.35M$8.92M$8.49M$8.29M
Long-term debt$134,808$135,730$136,644$137,550$138,447$139,336$140,217$141,089
Total debt$12.57M$10.01M$9.76M$9.67M$9.48M$9.06M$8.63M$8.43M
Total liabilities$21.83M$17.88M$17.45M$17.06M$16.69M$16.99M$15.41M$15.38M
Shareholders' equity-$21.21M-$17.26M-$16.83M-$16.35M-$15.83M-$16.21M-$14.81M-$14.82M
Net debt—$9.98M$9.75M$9.67M$9.41M$9.04M$8.59M$8.43M
Shares outstanding7.16B7.16B7.10B7.10B7.10B7.10B7.10B7.10B
Cash flow statement
Operating cash flow-$251,223-$327,791-$219,818-$250,770-$288,370-$405,006-$178,210$19,073
Capital expenditure——$0$0$0$26,052——
Free cash flow——-$219,818-$250,770-$288,370-$431,058——
Investing cash flow——$0$0-$25,000-$26,052$8,300$34,000
Financing cash flow$229,379$337,454$228,396$175,304$378,596$408,454$206,357-$53,073
Depreciation & amortization$2,358$2,501$2,572$2,769$3,163$2,145$1,860$1,860
Stock-based compensation$3,583$11,250$16,500$8,500$1,667———

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.